The Biosecurity Modernization and Innovation Act mandates that providers of nucleic acid synthesis services and equipment implement rigorous screening protocols to prevent the misuse of high-risk biological sequences.
August Pfluger
Representative
TX-11
The Biosecurity Modernization and Innovation Act establishes mandatory screening protocols for companies that synthesize nucleic acids or sell related equipment to prevent the misuse of high-risk biological sequences. The bill requires covered entities to verify customer identities, screen orders against a federal list of restricted sequences, and report suspicious activity to the Secretary of Commerce. Additionally, it grants the Secretary authority to enforce these standards through audits, investigations, and civil penalties to protect U.S. national security and public safety.
New Biosecurity Bill Mandates ID Checks and Vetting for DNA Sales: Compliance Kicks Off in One Year
Imagine you’re running a small biotech startup or a research lab. Right now, ordering custom DNA sequences is relatively straightforward. However, the Biosecurity Modernization and Innovation Act is about to add a significant layer of security to that process. The bill requires any business selling synthetic DNA or RNA—and even the companies selling the benchtop machines that make it—to act as a first line of defense against biological threats. Under Section 2, these companies must verify exactly who you are and what you plan to do with that genetic material before they hit 'print.'
The Digital Bouncer for DNA
For the office worker in logistics or the technician at a lab, this means the 'checkout' process for biological materials is getting a lot more intense. Covered entities—businesses that synthesize and sell nucleic acids—will be required to cross-reference every order against a federal list of 'covered sequences' (high-risk genetic codes) managed by the Secretary of Commerce. If a sequence looks like it could be used for something dangerous, the company has to refuse the sale and, in some cases, tip off the government. This isn't just for large-scale factories; it specifically includes 'benchtop' synthesizers, those microwave-sized machines that let researchers create DNA right in their own office. If you're a buyer, expect to provide more documentation and potentially face delays as companies perform these mandatory risk assessments.
The Cost of Compliance
While the goal is keeping us safe from bio-threats, the fine print reveals a heavy lift for businesses. Companies aren't just screening; they are required to undergo 'adversarial testing' and third-party audits to prove their systems work (SEC. 2(a)). For a small business owner, these independent assessments and the requirement to keep detailed records for five years could mean hiring new compliance staff or paying for expensive software. The stakes are high: if a company misses a red flag, the Secretary of Commerce can sue them for up to $750,000 per violation. There is a 30-day 'cure period' to fix mistakes before a lawsuit hits, but the threat of such a massive fine will likely make companies extremely cautious, potentially leading to 'false positives' where legitimate scientific research gets blocked.
A Secret List and Broad Powers
One of the trickier parts of this bill is how it defines what is 'dangerous.' The Secretary of Commerce has the power to decide which DNA sequences are 'covered' and restricted. While there is a process for the public to suggest changes to this list, the bill treats much of the underlying information as trade secrets (SEC. 2(g)). This means the average person—or even a competing researcher—might not have full transparency into why certain materials are restricted. Furthermore, this federal law will override most state-level rules on DNA screening, creating a single national standard. While this prevents a 'patchwork' of confusing state laws, it also concentrates a massive amount of power in one federal office to decide the future of biotech commerce.